Cumberland Pharmaceuticals reports $30.8 million year-to-date revenue, 12% increase
Reuters
Nov 05
Cumberland Pharmaceuticals reports $30.8 million year-to-date revenue, 12% increase
Cumberland Pharmaceuticals Inc. reported net revenues of $8.3 million for the third quarter of 2025 and $30.8 million for the first nine months of 2025, reflecting a 12% increase compared to the same period in 2024. Total operating expenses were $10.3 million for the third quarter and $32.3 million for the first nine months. The company recorded a net loss of approximately $1.9 million for the third quarter and a year-to-date net loss of about $1.4 million. Adjusted loss for the third quarter was $0.8 million, or $0.06 per share, while adjusted earnings for the first nine months were $1.9 million, or $0.13 per diluted share. As of September 30, 2025, Cumberland had total assets of $66 million, liabilities of $40 million, and shareholders' equity of $26 million, with $15 million in cash and cash equivalents. The company added a new FDA-approved brand to its commercial product portfolio during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL15581) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.